Boston Scientific defibrillators approved for extended longevity

Boston Scientific has announced that extended longevity projections for a range of its implantable cardioverter defibrillators (ICDs) and cardiac resynchronisation therapy defibrillators (CRT-Ds) have been approved by European regulators.

The company's Incepta, Energen, Punctua, Cognis and Teligen products have had their enhanced longevity profiles accredited with the European CE Mark, based on data from clinical studies.

Many of Boston Scientific's CRT-Ds have lifespans approaching eight years, with this figure exceeding ten years for certain ICD models.

This longevity is up to double that of comparable competitive device models, while many models are also supported by warranties spanning a similar period of time.

Michael Onuscheck, senior vice-president and president of the Europe, Middle East and Africa region at Boston Scientific, said: "We are pleased with the new labeling for our defibrillator products which provides doctors and patients with additional assurance about the longevity of these devices."

Earlier this month, the company announced its takeover of Vessix Vascular, a US-based medical technology firm that is responsible for the creation of the V2 Renal Denervation System.